PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8063619-3	1994	HL-60, ML1, and U937 leukemia cells treated with bufalin at 10(-8) M and above had condensed and fragmented nuclei.	bufalin	49-56	interleukin 17F	Homo sapiens	7-10	
7658701-2	1995	In the present study, we found that bufalin at concentrations of 10(-7) M and higher induced apoptosis in human leukemia cells, such as HL60, ML1, but not in mouse leukemia M1 cells.	bufalin	36-43	interleukin 17F	Homo sapiens	142-145	
1324788-2	1992	The present work was carried out to examine further the effect of bufalin on the growth and characteristics of human leukemia-derived cell lines U937, ML1, and HL60.	bufalin	66-73	interleukin 17F	Homo sapiens	151-154	
1324788-3	1992	At concentrations of 5-10 nM, bufalin decreased the growth of ML1 cells preferentially at the G2 phase and U937 cells at the S and G2 phases of the cell cycle.	bufalin	30-37	interleukin 17F	Homo sapiens	62-65	
1324788-4	1992	Bufalin, under these conditions, induced the differentiation of U937, ML1, and HL60 cells to monocyte/macrophage-like cells by measuring the expression of various differentiation markers, as assessed by morphology and histochemistry, and ability to phagocytose latex particles, to reduce nitroblue tetrazolium, and to develop Fc receptors.	bufalin	0-7	interleukin 17F	Homo sapiens	70-73	
1324788-5	1992	U937 and ML1 cells started to differentiate at 4 and 6 h, respectively, after treatment with 10 nM bufalin and showed maximum differentiation 72 h later.	bufalin	99-106	interleukin 17F	Homo sapiens	9-12	
1859424-2	1991	Bufalin, at a concentration as low as 10 nM, also produced a strong differentiation-inducing activity in three other human leukemia-derived cell lines (human promyelocytic HL60, monoblastic U937 and myeloblastic ML1).	bufalin	0-7	interleukin 17F	Homo sapiens	212-215